Contact Us
Drug Search Results
More Filters [+]

Alisporivir

Alternative Names: alisporivir, debio 025, deb025
Latest Update: 2024-03-16
Latest Update Note: PubMed Publication

Product Description

Alisporivir is the most advanced host-targeting antiviral in clinical development. Alisporivir blocks HCV replication by neutralizing the peptidyl-prolyl isomerase activity of the abundant host cytosolic protein, cyclophilin A. Due to its unique mechanism of antiviral action, alisporivir is pangenotypic, provides a high barrier for development of viral resistance, and does not permit cross-resistance to direct-acting antivirals.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23440335/)

Mechanisms of Action: Cyclophilin Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Debiopharm International
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Alisporivir

Countries in Clinic: France

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Acute Respiratory Distress Syndrome|COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CYCLOVID

P2

Completed

COVID-19

2022-01-19

CYCLOVID

P2

Active, not recruiting

COVID-19|Acute Respiratory Distress Syndrome

2021-02-26

Recent News Events

Date

Type

Title

03/16/2024

PubMed

 Taming Conformational Heterogeneity on Ion Racetrack to Unveil Principles that Drive Membrane Permeation of Cyclosporines.

08/16/2023

PubMed

 The novel cyclophilin inhibitor C105SR reduces hepatic ischaemia-reperfusion injury via mitoprotection.

08/01/2023

PubMed

 TRIM5α restricts poxviruses and is antagonized by CypA and the viral protein C6.

10/11/2021

News Article

 Global COVID-19 Pipeline Report 2021 - Comprehensive Insights About 400+ Companies and 400+ Pipeline Drugs

01/18/2021

News Article

 Phase II Research Against Covid-19 Launched in France With Debiopharm's Antiviral Alisporivir

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions